Heart disease in women

International Journal of Fertility and Women's Medicine

Volumn 45, Issue 6, 2000, Pages 350-357

  Giardina, E V ^a  

^a Columbia University ^*  (United States)

Author keywords

Clinical trials; Epidemiology; Gender specific medicine; Hormone replacement therapy; Women's medicine

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CHOLESTEROL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HYPOCHOLESTEROLEMIC AGENT; LIPID; PHYTOESTROGEN; VITAMIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIET THERAPY; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; KINESIOTHERAPY; LIFESTYLE; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; SMOKING CESSATION; SYMPTOMATOLOGY; THORAX PAIN; VERTIGO; WEIGHT REDUCTION;

CLINICAL TRIALS; DELIVERY OF HEALTH CARE; FEMALE; HEART DISEASES; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 0033637409     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Patterns in coronary heart disease - Morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population
2. Sex-based differences in early mortality after myocardial infarc-ion
3. Sex, clinical presentation and outcome in patients with acute coronary syndromes
4. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: Is there evidence for gender bias
5. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women
6. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiogram
7. Events in the cardiac arrhythmia suppression trial (CAST): Mortality in patients surviving open label titration but not randomized to double-blind therapy
8. Female gender as a risk factor for torsades de pointes. Associated with cardiovascular disease
9. Safety of bepridil
10. Cardiovascular drug therapy in women
11. Gender differences in survival in advanced heart failure
12. Treatment and prevention of hypertension
13. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial
14. MRC trial of treatment of mild hypertension: Pricipal result
15. Mortality in non-insulin-dependent diabetes
16. Manson HE Ridker PM, Gaziano JM, Hennekens CH (eds): Prevention of Myocardial Infarction. Oxford University Press, New York
17. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes
18. The primary prevention of coronary heart disease in women
19. Surveillance for selected tabacco-use behavior - United States, 1900-1994
20. A prospective study of parental history of myocardial infarction and coronary heart disease in women
21. Family history of heart attack as an independent predictor of death due to cardiovascular disease
22. Triglycerides and coronary risk in women and the elderly
23. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators
24. Hormone therapy to prevent disease and prolong life in post-menopausal women
25. Hormonal treatment of postmenopausal women
26. Estrogen and coronary heart disease in women
27. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. The Heart and Estrogen/Progestin Study
28. Effects of estrogen/progestin regimens on heart disease risk factaors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
29. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
30. Effect of postmenopausal hormones on inflammation sensitive proteins
31. Effect of postmenopausal hormones on inflammation sensitive proteins
32. Ethinyl estradiol acutely attenuates abnormal vasomotor responses to acetylcholine in postmenopausal women
33. Individual and combined effects of estrogen/progestin and lovstatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease
34. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
35. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
36. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk